Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 503173-14-6
2. 2,2,2-trifluoro-1-pyridin-2-yl-ethylamine
3. 2,2,2-trifluoro-1-pyridin-2-ylethanamine
4. 2,2,2-trifluoro-1-(pyridin-2-yl)ethan-1-amine
5. Mfcd05864540
6. (s)-2,2,2-trifluoro-1-(pyridin-2-yl)ethan-1-amine
7. Schembl566755
8. Dtxsid00649296
9. Albb-007848
10. Stk500794
11. Akos005171717
12. Ab22803
13. Ab39753
14. Ab39755
15. Sb37375
16. Bs-28515
17. Db-005800
18. Cs-0005384
19. En300-1930762
20. Alpha-(trifluoromethyl)-2-pyridinemethanamine
21. J-506742
22. 2,2,2-trifluoro-1-(2-pyridyl)-1-ethanamine
| Molecular Weight | 176.14 g/mol |
|---|---|
| Molecular Formula | C7H7F3N2 |
| XLogP3 | 0.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 1 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 38.9 |
| Heavy Atom Count | 12 |
| Formal Charge | 0 |
| Complexity | 146 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.
Lead Product(s): CT-996
Therapeutic Area: Nutrition and Weight Loss Brand Name: CT-996
Study Phase: Phase IProduct Type: Small molecule
Sponsor: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2024
Lead Product(s) : CT-996
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Not Applicable
Deal Type : Not Applicable
Roche Says Early-Stage Obesity Pill Results Were Based on Just Six Patients
Details : CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.
Brand Name : CT-996
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 11, 2024
Details:
CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.
Lead Product(s): CT-996
Therapeutic Area: Nutrition and Weight Loss Brand Name: CT-996
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2024
Lead Product(s) : CT-996
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Genentech Announces Positive Phase I Results of Oral GLP-1 Agonist CT-996 for Obesity
Details : CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.
Brand Name : CT-996
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 17, 2024
Details:
CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). it was designed to exhibit signaling bias on the GLP-1 receptor, resulting in activation of cAMP.
Lead Product(s): CT-996
Therapeutic Area: Endocrinology Brand Name: CT-996
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Lead Product(s) : CT-996
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). it was designed to exhibit signaling bias on the GLP-1 receptor, resulting in activation of cAMP.
Brand Name : CT-996
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
